62
Participants
Start Date
December 1, 2020
Primary Completion Date
December 14, 2024
Study Completion Date
March 7, 2025
Dupilumab SAR231893
Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Placebo
Pharmaceutical form:Injection solution Route of administration: Subcutaneous
Investigational Site Number : 0320005, Rosario
Investigational Site Number : 0320004, Mendoza
Investigational Site Number : 6820002, Riyadh
Investigational Site Number : 6820001, Riyadh
Eastern Virginia Medical School (EVMS) Medical Group - Otola Site Number : 8400008, Norfolk
National Allergy and Asthma Research, LLC Site Number : 8400002, Charleston
Emory University Hospital Midtown Campus Site Number : 8400009, Atlanta
Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400001, Tampa
Investigational Site Number : 7920001, Istanbul
Investigational Site Number : 7920007, Istanbul
Investigational Site Number : 7920006, Izmir
Investigational Site Number : 7920003, Izmir
Vanderbilt University Medical Center Site Number : 8400013, Nashville
Advanced ENT and Allergy Site Number : 8400004, Louisville
Investigational Site Number : 7920005, Malatya
Investigational Site Number : 3760001, Petah Tikva
South Louisiana Ear, Nose, Throat and Facial Plastic Surgery Site Number : 8400019, Mandeville
Investigational Site Number : 3760002, Rehovot
Ut- Houston Medical School Site Number : 8400010, Houston
USA Clinical Trials Site Number : 8400020, San Antonio
Alamo ENT Associates Site Number : 8400018, San Antonio
Investigational Site Number : 1560005, Beijing
Investigational Site Number : 1560001, Beijing
Investigational Site Number : 1560009, Shanghai
Investigational Site Number : 1560002, Nanjing
Investigational Site Number : 1560011, Qingdao
Investigational Site Number : 1560006, Hangzhou
Investigational Site Number : 3560006, Jodhpur
Investigational Site Number : 1560013, Fuzhou
Investigational Site Number : 1560004, Changsha
Investigational Site Number : 1560003, Chengdu
Investigational Site Number : 3560003, Coimbatore
Investigational Site Number : 3920010, Isehara
REX Clinical Trials Site Number : 8400017, Beaumont
Investigational Site Number : 0320003, CABA
Investigational Site Number : 0320001, CABA
Investigational Site Number : 0320002, Buenos Aires
Investigational Site Number : 1240001, Vancouver
Investigational Site Number : 1560012, Hefei
Investigational Site Number : 1560008, Taiyuan
Investigational Site Number : 3560008, New Delhi
Investigational Site Number : 3920006, Shizuoka
Investigational Site Number : 3920008, Bunkyo-ku
Investigational Site Number : 3920001, Meguro-ku
Investigational Site Number : 3920003, Shinagawa-ku
Investigational Site Number : 3920009, Shinjuku-ku
Investigational Site Number : 7920004, Adana
Lead Sponsor
Regeneron Pharmaceuticals
INDUSTRY
Sanofi
INDUSTRY